Targeting the IL-6/JAK/STAT3 signalling axis in cancer

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Nature Reviews Clinical Oncology

• Publication date

  2018-02-06

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/nrclinonc.2018.8PMID 29405201PMCID PMC5858971
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Signal Transducer and Activator of Transcription

  2020cited by this paper
• MicroRNA-218 functions as a tumor suppressor in lung cancer by targeting IL-6/STAT3 and negatively correlates with poor prognosis

  2017cited by this paper
• Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study.

  2017cited by this paper
• Do STAT3 inhibitors have potential in the future for cancer therapy?

  2017cited by this paper
• Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials

  2017cited by this paper
• IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model.

  2017cited by this paper
• Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.

  2017cited by this paper
• STAT3 Induces Immunosuppression by Upregulating PD-1/PD-L1 in HNSCC

  2017cited by this paper
• PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma

  2017cited by this paper
• JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer

  2017cited by this paper
• Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

  2017cited by this paper
• Hdac7 promotes lung tumorigenesis by inhibiting Stat3 activation

  2017cited by this paper
• Serum IL-6 and IL-8 Correlate with Prognostic Factors in Ovarian Cancer

  2017cited by this paper
• Severe cytokine release syndrome in a patient receiving PD‐1‐directed therapy

  2017cited by this paper
• Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series

  2017cited by this paper
• Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-α is a biomarker of nivolumab recativity.

  2017cited by this paper
• The promise of Janus kinase inhibitors in the treatment of hematological malignancies

  2017cited by this paper
• Varied immuno-related adverse events induced by immune-check point inhibitors - Nivolumab-associated psoriasiform dermatitis related with increased serum level of interleukin-6.

  2017cited by this paper
• JAK2 inhibitors for myeloproliferative neoplasms: what is next?

  2017cited by this paper
• Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies

  2016cited by this paper
• Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia.

  2016cited by this paper
• Role of interleukin-6 in cancer progression and therapeutic resistance

  2016cited by this paper
• IL6 Trans-signaling Promotes KRAS-Driven Lung Carcinogenesis.

  2016cited by this paper
• Inhibition of STAT3 with the Generation 2.5 Antisense Oligonucleotide, AZD9150, Decreases Neuroblastoma Tumorigenicity and Increases Chemosensitivity

  2016cited by this paper
• IL-6 Inhibition With MEDI5117 Decreases The Fraction of Head and Neck Cancer Stem Cells and Prevents Tumor Recurrence1,2

  2016cited by this paper
• Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn’s disease: a case report

  2016cited by this paper
• The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations.

  2016cited by this paper
• Cancer-associated fibroblasts promote endometrial cancer growth via activation of interleukin-6/STAT-3/c-Myc pathway.

  2016cited by this paper
• Targeting JAK kinase in solid tumors: emerging opportunities and challenges

  2016cited by this paper
• Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial

  2016cited by this paper
• A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors.

  2016cited by this paper
• The biology behind interleukin-6 targeted interventions

  2016cited by this paper
• Antitumor effects of interleukin‐6 (IL‐6)/interleukin‐6 receptor (IL‐6R) signaling pathway inhibition in clear cell carcinoma of the ovary

  2016cited by this paper
• The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis.

  2016cited by this paper
• Tumor-associated GM-CSF overexpression induces immunoinhibitory molecules via STAT3 in myeloid-suppressor cells infiltrating liver metastases

  2016cited by this paper
• The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer.

  2016cited by this paper
• Increased interleukin-6 expression is associated with poor prognosis and acquired cisplatin resistance in head and neck squamous cell carcinoma

  2016cited by this paper
• Bypassing STAT3-mediated inhibition of the transcriptional regulator ID2 improves the antitumor efficacy of dendritic cells

  2016cited by this paper
• Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer.

  2016cited by this paper
• IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer

  2016cited by this paper
• Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis

  2016cited by this paper
• Rationally Repurposing Ruxolitinib (Jakafi®) as a Solid Tumor Therapeutic

  2016cited by this paper
• Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma

  2016cited by this paper
• Characterization of Patients With Advanced Pancreatic Cancer and High Serum Interleukin-6 Levels

  2015cited by this paper
• Signal Transducer and Activator of Transcription 4 in Liver Diseases

  2015cited by this paper
• Activating somatic mutations outside the SH2-domain of STAT3 in LGL leukemia

  2015cited by this paper
• A phase 2, randomized, double‐blind, placebo‐controlled study of siltuximab (anti‐IL‐6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma

  2015cited by this paper
• Emerging Strategies for Cancer Immunoprevention

  2015cited by this paper
• The Opposing Function of STAT3 as an Oncoprotein and Tumor Suppressor Is Dictated by the Expression Status of STAT3β in Esophageal Squamous Cell Carcinoma

  2015cited by this paper
• Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies.

  2015cited by this paper
• Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors

  2015cited by this paper
• Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

  2015cited by this paper
• A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer.

  2015cited by this paper
• Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma

  2015cited by this paper
• IL-6 as a keystone cytokine in health and disease

  2015cited by this paper
• Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer

  2015cited by this paper
• Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.

  2015cited by this paper
• Frequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer

  2015cited by this paper
• Routine clinical markers of the magnitude of the systemic inflammatory response after elective operation: a systematic review.

  2015cited by this paper
• The assessment of the prognostic value of tumor markers and cytokines as SCCAg, CYFRA 21.1, IL-6, VEGF and sTNF receptors in patients with squamous cell cervical cancer, particularly with early stage of the disease

  2015cited by this paper
• Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis

  2015cited by this paper
• Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells

  2015cited by this paper
• Inhibition of IL‐6 signaling significantly reduces primary tumor growth and recurrencies in orthotopic xenograft models of pancreatic cancer

  2015cited by this paper
• Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis.

  2015cited by this paper
• AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer

  2015cited by this paper
• JAK Kinase Inhibition Abrogates STAT3 Activation and Head and Neck Squamous Cell Carcinoma Tumor Growth12

  2015cited by this paper
• Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies

  2015cited by this paper
• Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.

  2015cited by this paper
• Inhibition of IL-6/STAT3 axis and targeting Axl and Tyro3 receptor tyrosine kinases by apigenin circumvent taxol resistance in ovarian cancer cells.

  2015cited by this paper
• Hitting the right spot: Mechanism of action of OPB‐31121, a novel and potent inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3)

  2015cited by this paper
• Phase 1 and pharmacological trial of OPB‐31121, a signal transducer and activator of transcription‐3 inhibitor, in patients with advanced hepatocellular carcinoma

  2015cited by this paper
• Increased expression of interleukin-6 predicts poor response to chemoradiotherapy and unfavorable prognosis in oral squamous cell carcinoma

  2015cited by this paper
• A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011)

  2015cited by this paper
• Trans-Signaling Is a Dominant Mechanism for the Pathogenic Actions of Interleukin-6 in the Brain

  2014cited by this paper
• Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells.

  2014cited by this paper
• Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer

  2014cited by this paper
• Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity.

  2014cited by this paper
• IL-22(+)CD4(+) T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L.

  2014cited by this paper
• Original ResearchFull Report: Basic and Translational—Alimentary TractA microRNA 221– and 222–Mediated Feedback Loop Maintains Constitutive Activation of NFκB and STAT3 in Colorectal Cancer Cells

  2014cited by this paper
• IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis.

  2014cited by this paper
• Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors

  2014cited by this paper
• Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma.

  2014cited by this paper
• Loss of STAT3 in murine NK cells enhances NK cell-dependent tumor surveillance.

  2014cited by this paper
• Interleukin-6 and its receptors: a highly regulated and dynamic system.

  2014cited by this paper
• Tofacitinib versus methotrexate in rheumatoid arthritis.

  2014cited by this paper
• A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors

  2014cited by this paper
• STAT transcription factors in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention

  2014cited by this paper
• Safety and tolerability of intrathecal delivery of autologous bone marrow nucleated cells in children with cerebral palsy: an open-label phase I trial.

  2014cited by this paper
• Antitumor Efficacy of the Anti-Interleukin-6 (IL-6) Antibody Siltuximab in Mouse Xenograft Models of Lung Cancer

  2014cited by this paper
• Systemic Administration of a Cyclic Signal Transducer and Activator of Transcription 3 (STAT3) Decoy Oligonucleotide Inhibits Tumor Growth without Inducing Toxicological Effects

  2014cited by this paper
• STAT3: A Novel Molecular Mediator of Resistance to Chemoradiotherapy

  2014cited by this paper
• STAT3, STAT4, NFATc1, and CTCF Regulate PD-1 through Multiple Novel Regulatory Regions in Murine T Cells

  2014cited by this paper
• Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.

  2014cited by this paper
• Tofacitinib versus methotrexate in rheumatoid arthritis.

  2014cited by this paper
• Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis : anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour-stroma interaction

  2014cited by this paper
• A phase 2 multicentre study of siltuximab, an anti‐interleukin‐6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma

  2013cited by this paper
• Stat3 Inhibitor Stattic Exhibits Potent Antitumor Activity and Induces Chemo- and Radio-Sensitivity in Nasopharyngeal Carcinoma

  2013cited by this paper
• Inhibitory effects of STAT3 decoy oligodeoxynucleotides on human epithelial ovarian cancer cell growth in vivo.

  2013cited by this paper
• Both STAT1 and STAT3 are favourable prognostic determinants in colorectal carcinoma

  2013cited by this paper
• Icaritin Inhibits JAK/STAT3 Signaling and Growth of Renal Cell Carcinoma

  2013cited by this paper

• Targeting neuropilin-1 and neutralizing interleukin-6 inhibits cancer stem cell formation in bladder cancer cells.

  2026cites this paper
• Integrative pan-cancer analysis reveals the prognostic and immunological significance of SLC7 family cationic amino acid transporters

  2026influential citation
• SHP2 promotes osteosarcoma via regulating STAT3/TET3/HOXB2 signaling

  2026cites this paper
• The identification of RNA splicing aberrations and their potential regulatory network in Chinese non-small cell lung cancer.

  2026cites this paper
• METTL14 modulates the nasopharyngeal carcinoma microenvironment via m6A-modified YWHAH identified through single-cell and machine learning analyses

  2026cites this paper
• Personalizing therapies over the course of hormone receptor‐positive/HER2‐negative metastatic breast cancer

  2026cites this paper
• Targeting PLK1 potentiates the antitumor efficacy of EGFR-TKIs through inhibiting the JAK1/STAT3 pathway

  2026cites this paper
• The interplay between cytokines and immune checkpoints in breast cancer therapy.

  2026cites this paper
• IL-6 and Immunosenescence in the Current Research on Immunotherapy for Elderly Lung Cancer Patients

  2026cites this paper
• A multifunctional hydrogel for inhibiting metastasis and recurrence of hepatocellular carcinoma via inflammation alleviation, metabolism regulation, and immune activation

  2026cites this paper
• Cancer Stemness and Dedifferentiation in Anaplastic Thyroid Carcinoma: Insights into a Multigenic, Microenvironmental Network and the Role of CD44.

  2026cites this paper
• JAK2 pathogenic variants in ischemic stroke: low prevalence and pre-screening model

  2026cites this paper
• Identification of Tumor- and Immunosuppression-Driven Glioblastoma Subtypes Characterized by Clinical Prognosis and Therapeutic Targets

  2026cites this paper
• Cardamonin induces apoptosis of colorectal cancer cells via targeted inhibition of the JAK/STAT3/epithelial-mesenchymal transition (EMT) signaling axis

  2026cites this paper
• Artificial Intelligence-Enhanced Molecular Profiling of JAK-STAT Pathway Alterations in FOLFOX-Treated Early-Onset Colorectal Cancer

  2026cites this paper
• Mechanism identification of an herbal decoction for potential treatment of diffuse large B-cell lymphoma using network pharmacology and experimental validation.

  2026cites this paper
• EP4 stimulation promotes cell adhesion and migration via IL-6 signaling in oral squamous cell carcinoma

  2026cites this paper
• Senescent cancer-associated fibroblasts in cancer progression: From formation to therapeutic opportunities.

  2026cites this paper
• Low-dose 5-hydroxymethylfurfural mitigates radiation -induced intestinal toxicity via HIF2α-driven IL22/STAT3 signaling enhancement

  2026cites this paper
• Chronic and non-canonical cGAS–STING activation: implications for health, disease, cancer, and emerging therapeutic opportunities

  2026cites this paper
• From laboratory bench to surgical room: Molecular profiling and single-cell technologies in precision surgery for colorectal cancer patients.

  2026cites this paper
• Targeting JAK/STAT axis in solid tumors: resolving the therapeutic paradox through upstream suppression and downstream disruption

  2026cites this paper
• Cytokines, Signaling and Epigenetic Mechanisms: Shaping the Acute Lymphoblastic Leukemia Microenvironment

  2026cites this paper
• The CALLY index as a comprehensive inflammation-nutrition-immunity marker for prognosis in gastric cancer surgery.

  2026cites this paper
• Monocytes Strongly Induce (MYO)Fibroblast Contraction in a New 3D Skin Model to Understand the Inflammation-Fibrosis Axis in Systemic Sclerosis

  2026cites this paper
• Integrative cross‐tissue and spatially resolved single‐cell profiling uncovers tumour‐educated inflammatory remodelling of tissue‐resident macrophage ecosystem with immunotherapeutic prognostic significance in pan‐cancer

  2026cites this paper
• Molecular Remodeling of Peritumoral Tissue in Clear Cell Renal Cell Carcinoma: Insights into Inflammaging and Prognostic Markers

  2026cites this paper
• A CD36-Targeting Thermosensitive Berberine Nanogel Blocks Tumor Lipid Hijacking and Potentiates Anti-PD-L1 Immunotherapy in Triple-Negative Breast Cancer.

  2026cites this paper
• Sialylation-immune-related lncRNA LINC01605 promotes tumor-infiltrating CD8+ T cell exhaustion and malignancy of clear cell renal cell carcinoma

  2026cites this paper
• B cell immunity and therapeutic opportunities in brain metastases

  2026cites this paper
• Tumor-derived neutrophil extracellular trap–associated DNA impairs treatment efficacy in breast cancer via CCDC25-dependent epithelial-mesenchymal transition

  2026cites this paper
• Pharmacological targeting of the JAK-STAT pathway: new concepts and emerging indications.

  2026cites this paper
• PBRM1 Deficiency Reshapes an Immune Suppressive Microenvironment Through Epigenetic Tuning of PBRM1-KDM5C-IL6 Axis in ccRCC.

  2026cites this paper
• Quercetin targets IL6/JAK1/STAT3/MMP9 signaling to attenuate breast cancer progression in diabetic comorbidity: A multi-omics and experimental study.

  2026cites this paper
• Lung Cancer Cell-Macrophage Interaction System for Signal Pathway-Based Logic Analysis and Drug Testing.

  2026cites this paper
• IL-6/STAT3 signaling in prostate cancer: CAF-driven immune evasion and therapeutic opportunities

  2026cites this paper
• BMP5 mediates macrophage-driven Oral leukoplakia carcinogenesis.

  2026cites this paper
• Research status and prospects of molecular pathological mechanisms and novel therapeutic targets of osteosarcoma: a systematic review

  2026cites this paper
• Leveraging glucan-induced trained immunity for the epigenetic and metabolic rewiring of macrophages to enhance colorectal cancer vaccine response

  2026cites this paper
• Magnolia officinalis Lignans induce apoptosis and epigenetic reprogramming via the miR-148a-3p/DNMT-1/UTF-1 axis in pancreatic cancer cells.

  2026cites this paper
• Tumor-intrinsic ETV5 expression promotes PMN-MDSC-mediated immune evasion and immune checkpoint inhibitor resistance by activating the JAK2/STAT3/CCL2 axis

  2026cites this paper
• Cytokine storm divergence in viral infections of the upper respiratory tract.

  2026cites this paper
• Genetic dissection of signalling pathways that mediate iron-related tumor growth in a Drosophila model

  2026cites this paper
• Macrophage Extracellular Traps in Immunity and Cancer.

  2026cites this paper
• Theoretical investigation on the construction of hair follicle membranes and the transdermal drug delivery mechanisms of JAK inhibitors via distinct pathways

  2026cites this paper
• RNA ‐binding protein RBMS1 : A new target for cancer diagnosis and treatment

  2026cites this paper
• Ellagic Acid Prevents Obesity in High-Fat Diet-Fed Rats by Ameliorating Oxidative Stress via Modulation of the PPARG/STAT3/p-AKT1 Axis

  2026cites this paper
• Oxidative Stress and Inflammation in Colorectal Cancer–Redox–Immune Crosstalk, Biomarkers, and Translational Implications: A Qualitative Systematic Review

  2026cites this paper
• CD4+ T‐Cell‐Intrinsic IL‐6 Is Critical for Th17 Differentiation and Dampened Responsiveness to CD8+ T Cell‐Mediated Suppression

  2026cites this paper
• DANCR Promotes Metastasis and Proliferation in Bladder Cancer Cells by Enhancing IL-11-STAT3 Signaling and CCND1 Expression.

  2026cites this paper
• Cytokine Profiling in Cutaneous Melanoma: The Emerging Role of Interleukins in Prognostic Stratification with an Up-to-Date Overview of Published Data.

  2026cites this paper
• Mechanisms of therapy resistance in the tumor microenvironment: Insights from antibody array-based cytokine profiling.

  2026cites this paper
• An Integrated Strategy for the Discovery, Recombinant Expression, and Biological Evaluation of Anti-Inflammatory Peptides from Rice Protein.

  2026cites this paper
• FomA-Containing Outer Membrane Vesicles of Fusobacterium Nucleatum Facilitate Bladder Cancer Lymphatic Metastasis via IL-6-Dependent M2b Macrophage Polarization.

  2026cites this paper
• Escherichia coli promotes colorectal cancer metastasis by maintaining enhancer-promoter loops through releasing neutrophil extracellular traps.

  2026cites this paper
• Mechanistic Links Between the Gut Microbiome and Longevity Therapeutics.

  2026cites this paper
• Ferroptosis-based nano-assembly enhanced breast cancer therapy by inhibiting intratumor bacteria

  2026cites this paper
• Sulfasalazine induces ferroptosis by regulating the PIAS3/JAK1/STAT3 pathway to prevent brain metastases of hepatocellular carcinoma

  2026cites this paper
• Prostate Cancer, JAK/STAT3 Dysregulation, and Flavonoids: Is There a Possible Link?

  2026cites this paper
• CATHEPSIN D: MOLECULAR, GENETIC AND FUNCTIONAL ASPECTS IN THE TUMOR MICROENVIRONMENT

  2026cites this paper
• Comprehensive pan-cancer analysis reveals SH3GLB1 is a novel prognostic biomarker with immunomodulatory potential

  2026cites this paper
• An Anoikis Resistance Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Blockades in Gastric Cancer

  2026cites this paper
• Characterizing the Head and Neck Cancer Microenvironment: Implications for Immunotherapy and Prognosis.

  2026cites this paper
• Thimerosal Inhibits Tumor Malignant Progression through Direct Action and Enhancing the Efficacy of PD-1-Based Immunotherapy

  2026cites this paper
• Modified Wen Luo Tong Alleviated Chemotherapy-Induced Peripheral Neuropathy via Regulating the CX3CL1/CX3CR1 Axis Through Inhibiting NF-κB and STAT3 Pathways

  2026cites this paper
• Brucella abortus infection exploits ZDHHC3-mediated STAT3 palmitoylation to regulate host responses and promote persistence

  2026influential citation
• Hydrogel-based delivery of cytokines in cancer immunotherapy: Latest evidence and therapeutic outcomes.

  2026cites this paper
• Tocilizumab improves the efficacy of anti-PD-1 in a patient with advanced gastroesophageal junction cancer: a case report

  2025cites this paper
• Suprabasin promotes gastric cancer liver metastasis via hepatic stellate cells-mediated EGF/CCL2/JAK2 intercellular signaling pathways

  2025cites this paper
• Goistrat: gene-of-interest-based sample stratification for the evaluation of functional differences

  2025cites this paper
• Chromosomal Instability and IL6-Mediated Inflammatory Signaling in Human Lymphoma Cells

  2025cites this paper
• Small open reading frame-encoded microproteins in cancer: identification, biological functions and clinical significance

  2025cites this paper
• Role of antidiarrheal agents nifuroxazide in antitumor multi‑target anticancer, multi‑mechanism anticancer drug (Review)

  2025cites this paper
• Role of Senescence-Associated Biomarkers and Immune Dynamics in Predicting Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer

  2025cites this paper
• Amniotic fluid-derived mesenchymal stem cells as a therapeutic tool against cytokine storm: a comparison with umbilical cord counterparts

  2025cites this paper
• Clonal hematopoiesis of indeterminate potential: contribution to disease and promising interventions

  2025cites this paper
• CircNF1 modulates the progression and immune evasion of esophageal squamous cell carcinoma through dual regulation of PD-L1

  2025cites this paper
• Spliceosome protein EFTUD2: A potential pathogenetic factor in tumorigenesis and some developmental defects (Review)

  2025cites this paper
• Effects of SB939 are mediated by STAT3 to inhibit breast cancer cell metastasis-related genes

  2025cites this paper
• YWHAG promotes the progression of lung adenocarcinoma through the JAK2/STAT3 pathway

  2025cites this paper
• [High expression of hexokinase 2 promotes proliferation, migration and invasion of colorectal cancer cells by activating the JAK/STAT pathway and regulating tumor immune microenvironment].

  2025cites this paper
• Integrative Analysis of EGF, OSM, and TGFB Signaling Pathways Reveals Synergistic Mechanisms Driving Cell Motility Through CXCR2 Chemotactic Signaling and CREB Activation

  2025cites this paper
• IL-6 underlies microenvironment immunosuppression and resistance to therapy in glioblastoma

  2025influential citation
• The tumor microenvironment is an ecosystem sustained by metabolic interactions.

  2025cites this paper
• Genomic profiling reveals molecular heterogeneity in patients with Richter transformation (RT) and chronic lymphocytic leukemia (CLL)

  2025cites this paper
• Linagliptin Mitigates DMH‐Induced Colorectal Cancer in Rats: Crosstalk Between NFAT and IL‐6/JAK2/STAT3/NF‐κB Signaling Hubs

  2025cites this paper
• The Impact of Ultra-Processed Foods on Cardiovascular Diseases and Cancer: Epidemiological and Mechanistic Insights

  2025cites this paper
• Microglia-Derived Brain Macrophages Associate with Glioblastoma Stem Cells: A Potential Mechanism for Tumor Progression Revealed by AI-Assisted Analysis

  2025cites this paper
• Chromosomal Instability Is Associated with cGAS–STING Activation in EGFR-TKI Refractory Non-Small-Cell Lung Cancer

  2025cites this paper
• Clinical Applications of Oligonucleotides for Cancer Therapy.

  2025cites this paper
• Hepatic Stellate Cells Functional Heterogeneity in Liver Cancer

  2025cites this paper
• STK31 drives tumor immune evasion through STAT3-IL-6 mediated CD8+ T cell exhaustion

  2025cites this paper
• The clinical significance of T-cell regulation in hypertension treatment

  2025cites this paper
• Text Mining-Based Drug Discovery and MAPK14, STAT3, VEGFA as Novel Candidate Genes in Post-Tuberculosis Tracheobronchial Stenosis.

  2025cites this paper
• A combinatorial screening protocol for identifying novel and highly potent dual-target inhibitor of BRD4 and STAT3 for kidney cancer therapy

  2025cites this paper
• Advances in Interleukin-6 Family Cytokines and the Role in Respiratory Diseases

  2025cites this paper
• Adipose-derived stem cells enhance the tumorigenic potential of pre-malignant breast epithelial cells through paracrine activation of PI3K–AKT pathway

  2025cites this paper
• Chemotherapy with a molecular rational basis, pentoxifylline as a promising antitumor drug

  2025cites this paper
• Mechanisms, assessment, and exercise interventions for skeletal muscle dysfunction post-chemotherapy in breast cancer: from inflammation factors to clinical practice

  2025cites this paper
• B7-H3-mediated deubiquitination stabilizing CYP1B1 expression promotes chemotherapy resistance in colorectal cancer.

  2025cites this paper